NEU neuren pharmaceuticals limited

Ann: Neuren initiates development of NNZ-2591 to treat HIE, page-49

  1. 1,592 Posts.
    lightbulb Created with Sketch. 818
    I'm assuming it will be similar to a stroke trial, presumably the primary gauge of efficacy will be MRIs or ECGs to monitor either decreases in infarct volume, improvements in any penumbral areas,or improvement in brain activity. The stroke trials run by Clinuvel and Argenica don't use control groups, they gauge improvement over SoC with MRIs.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$17.55
Change
0.540(3.17%)
Mkt cap ! $2.211B
Open High Low Value Volume
$17.48 $18.44 $17.40 $16.43M 922.3K

Buyers (Bids)

No. Vol. Price($)
4 2624 $17.53
 

Sellers (Offers)

Price($) Vol. No.
$17.70 1000 1
View Market Depth
Last trade - 16.10pm 07/08/2025 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.